对抗呼吸系统疾病的曼吉费林:药理目标和前景
Kazi Ahsan Ahmed1,2, Nusrat Afrin1, Popy Ghosh2
1ABEx Bio-Research Center, Dhaka, Bangladesh.
Pharmacology research & perspectives
|August 10, 2025
概括
曼吉费林是一种天然的多,通过对抗感染和减少炎症,有望治疗呼吸道疾病. 需要进一步的临床试验来证实它对呼吸系统疾病的治疗益处.
科学领域:
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 呼吸系统疾病导致全球显著的死亡率和发病率.
- 抗生素耐药性和有限的治疗选择推动了对新疗法的研究.
- 自然产品正在研究它们在治疗呼吸道感染方面的潜力.
研究的目的:
- 审查C-glycosyl xanthone多的mangiferin作为呼吸道疾病治疗剂的潜力.
- 探索曼吉费林的药理活动和治疗呼吸道感染的治疗前景.
主要方法:
- 关于曼吉费林和呼吸系统疾病的科学研究的文献综述.
- 分析曼吉费林的作用机制,包括抗感染,抗炎和免疫调节作用.
- 评估曼吉费林在向呼吸道感染中涉及的各种途径方面的潜力.
主要成果:
- 曼吉费林表现出抗感染性质,减少炎症,调节免疫反应,并增强宿主防御.
- 它独特的C-glycosyl xanthone结构有助于其多样化的药理活动.
- 曼吉费林向了与呼吸系统疾病病变相关的多种途径.
结论:
- 曼吉费林显示出作为呼吸系统疾病治疗选择的巨大潜力.
- 它的多面性药理学特征需要进一步研究以获得临床应用.
- 需要进行额外的临床验证,以确定曼吉费林在治疗呼吸系统疾病中的有效性和安全性.
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
573
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
573
Acute Respiratory Failure-V
200
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
200
Drugs Used in Upper Respiratory Disorders: Overview
356
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
356
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
425
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
425
Antiasthma Drugs: Muscarinic Receptor Antagonists
443
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
443
Asthma: Pathogenesis and Management
573
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
573


